MedTrace Logo

Safety and Efficacy Study of SOM230 s.c. in Cluster Headache

NCT02619617 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2021-01-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to determine if SOM230 is safe and effective for the treament of cluster headache.

Conditions

  • Cluster Headache - Episodic and Chronic

Interventions

DRUG

SOM230

The study evaluated SOM230 vs Placebo

DRUG

Placebo

The study evaluated SOM230 vs Placebo

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2018-09-25
Completion
2018-09-25

Countries

  • United States
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02619617 on ClinicalTrials.gov